06 Feb 2026

Asia powers poultry vaccine market growth to 2036

Poultry vaccines are becoming non-negotiable in the region's intensive systems, ensuring productivity, food safety, and compliance with global trade standards.

aviNews Asia

SAVE IN THE LIBRARY PDF FILE

The poultry vaccine market is projected to reach USD 7.8 billion in 2026 and grow to USD 19.2 billion by 2036, a report by Future Market Insights said. This expansion reflects a compound annual growth rate of 9.4%, driven by preventive health strategies in intensive poultry systems.

Vaccination has become a structural necessity in high-density broiler, layer, and breeder operations. Producers rely on immunization to stabilize flock performance, reduce mortality, and maintain predictable processing volumes.

Asia leads global growth

Asian markets are at the forefront of this expansion. India, China, and other regional producers are adopting standardized vaccination schedules to protect productivity and meet regulatory expectations.

India: CAGR of 11.7%, supported by rapid broiler integration and government surveillance programs.
China: CAGR of 10.5%, driven by farm consolidation, food safety oversight, and domestic vaccine manufacturing.
Other Asian contributors: Strong growth in vertically integrated systems, aligning vaccination with biosecurity and export requirements.

These countries emphasize preventive immunization not as a reaction to outbreaks but as a core production control embedded in daily management.

Drivers of demand

The report highlights several factors shaping vaccine adoption in Asia:

Continue after advertising.

High stocking densities increase exposure to viral diseases.
Government disease surveillance programs reinforce routine immunization.
Hatchery-based vaccine delivery ensures uniform flock protection.
National disease control policies emphasize preventive strategies.
Domestic manufacturing supports reliable supply chains.

These drivers reflect a shift toward long-term risk management rather than episodic responses to disease events.

Product and application trends

Live attenuated vaccines dominate utilization, accounting for 42% of demand. Their ability to induce rapid immunity and suitability for mass administration make them central to Asian programs. Inactivated vaccines represent 34%, valued for safety and maternal antibody transfer. Recombinant vaccines hold 24%, targeting specific pathogens with improved differentiation capability.

Application demand is shaped by persistent threats:

Newcastle disease: 28%
Avian influenza: 26%
Infectious bursal disease: 24%
Other diseases: 22%

These figures highlight the importance of regulatory oversight and regional disease prevalence in shaping vaccination schedules.

Competitive landscape

Global players such as Zoetis, Boehringer Ingelheim, Ceva, Elanco, and Phibro are active in Asia.

Their portfolios align with integrated poultry systems, offering solutions that balance immune strength, scalability, and operational practicality. Engagement with hatcheries and veterinary services ensures consistent adoption across diverse production environments.

Where the market is headed

The report concludes that Asia’s poultry vaccine demand reflects structural changes in production systems. Preventive immunization is now embedded in biosecurity, food safety, and supply chain assurance.

With India and China leading growth, the region will remain central to global market expansion through 2036.

PDF FILE